Biogen(BIIB) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported a strong fourth quarter and full-year performance, with non-GAAP diluted EPS of $1.99 for Q4 and $15.28 for the full year 2025, exceeding expectations [26][35] - Total revenue for the full year 2025 was $9.9 billion, up 2% compared to 2024, with growth products generating $3.3 billion, a 19% increase [4][28] - Free cash flow for the year was $2.1 billion, with cash and marketable securities totaling $4.2 billion at year-end [28][33] Business Line Data and Key Metrics Changes - Growth products generated over $800 million in Q4 2025, up 6% year-over-year, and $3.3 billion for the full year, up 9% [27] - Leqembi saw fourth quarter in-market sales of approximately $134 million, up 10% sequentially and 54% year-over-year [29] - Spinraza revenue in Q4 was $356 million, with U.S. revenue of $169 million, showing resilience despite a competitive market [30] Market Data and Key Metrics Changes - The U.S. MS business generated total revenue of $9.9 billion for the full year 2025, reflecting a 2% increase from 2024 [28] - Leqembi maintained over 60% market share in the anti-amyloid therapy market, indicating strong competitive positioning [8] - The market for anti-amyloid therapy has more than doubled, with increasing physician reports of patient benefits [11] Company Strategy and Development Direction - The company is focusing on growth through new medicines, with a pipeline that includes several first-in-class treatments [12][22] - Strategic investments are being made in pre-launch activities for lupus and nephrology products, with a focus on maintaining financial discipline [34][35] - The company aims to build a bridge to growth by expanding its early-stage pipeline and pursuing business development opportunities [19][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future growth of the company, particularly with expected approvals for key products like Leqembi and Litifilimab [18][25] - The company anticipates a decline in total revenue by a mid-single-digit percentage for 2026, primarily due to competitive pressures in the MS market [36] - Management highlighted the importance of upcoming phase 3 data readouts for Litifilimab and Felzartamab, which could significantly impact future growth [19][25] Other Important Information - The company has secured priority review for Leqembi and received breakthrough therapy designation for Litifilimab, indicating strong external recognition of its pipeline [21][24] - The company is actively pursuing collaborations and business development opportunities to enhance its pipeline and market position [6][8] Q&A Session Summary Question: Can you walk us through the cadence of Leqembi sales growth this year? - Management indicated a persistency rate of about 70% for patients transitioning to maintenance therapy, with expectations for continued sequential growth [39][40] Question: When do you think Biogen's top line could return to growth? - Management noted that growth products have outstripped declines in the MS portfolio, but positive phase 3 results and potential acquisitions are crucial for returning to growth [45][46] Question: How important is the upcoming BIIB080 data? - Management emphasized the significance of the data, noting that the neurology community is closely watching the potential impact of tau reduction on cognition [52][53] Question: What is the conviction level for Litifilimab's phase 3 trials? - Management expressed high conviction in Litifilimab due to its targeting of the BDCA2 pathway and previous positive data from earlier studies [63][64] Question: How important is it to hit the eGFR endpoint for Felzartamab? - Management acknowledged the importance of the eGFR endpoint while focusing on the primary endpoint, with ongoing evaluations for broader applications in other transplants [68][70]